Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients

Journal of Clinical Pharmacology

Volumn 39, Issue 1, 1999, Pages 41-46

  Zhi, Jianguo ^a   Mulligan, Thomas E ^b   Hauptman, Jonathan B ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ENZYME INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPASE INHIBITOR; LOW DENSITY LIPOPROTEIN; ORAL ANTIDIABETIC AGENT; PLACEBO; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; HUMAN; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS; LACTONES; LIPASE; OBESITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032924255     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007543     Document Type: Article

References (11)

1. Hadváry P, Lengsfeld H, Wolfer H: Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 1988;256:357-361.
2. Borgström B: Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta 1988;962:308-316.
3. Drent ML, van der Veen EA: Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes 1993;17:241-244.
4. Zhi J, Melia AT, Eggers H, Joly R, Patel IH: Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995;35:1103-1108.
5. Zhi J, Melia AT, Funk C, Viger-Chougnet A, Hopfgartner G, Lausecker B, Wang K, Fulton J, Gabriel L, Mulligan TE: Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996;36:1006-1011.
6. Van Gaal LF, Broom JI, Enzi G, Toplak H: Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 1998;54:125-132.
7. James WPT, Avenell A, Broom J, Whitehead J: A one-year trial to assess the value of orlistat in the management of obesity. Int J Obesity 1997;21(Suppl. 3):S24-S30.
8. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, Krempf M: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-172.
9. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al: Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998;21:1288-1294.
10. Bennett PK, Li YT, Edom R, Henion J: Quantitative determination of orlistat (tetrahydrolipstatin, Ro 18-0647) in human plasma by high-performance liquid chromatography coupled with ion spray tandem mass spectrometry. J Mass Spectrom 1997;32:739-749.
11. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH: Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994;56:82-85.